Harold Davidson & Associates Inc. Allogene Therapeutics, Inc. Transaction History
Harold Davidson & Associates Inc.
- $183 Billion
- Q1 2025
A detailed history of Harold Davidson & Associates Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Harold Davidson & Associates Inc. holds 252,350 shares of ALLO stock, worth $355,813. This represents 0.2% of its overall portfolio holdings.
Number of Shares
252,350
Previous 232,615
8.48%
Holding current value
$355,813
Previous $495 Million
25.64%
% of portfolio
0.2%
Previous 0.24%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$26.4 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$23.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$17.3 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$15.6 Million5.97% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$14.7 Million1.06% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $203M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...